Search Result

Results for "

T lymphocytes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (3) Apoptosis (8) Arenavirus (4) Autophagy (4) Bacterial (5) CD28 (1) CD3 (1) CTLA-4 (5) CXCR (1) Deubiquitinase (1) DOCK (1) Drug Metabolite (3) EBV (1) EGFR (1) Endogenous Metabolite (4) Epigenetic Reader Domain (1) Ferroptosis (1) FKBP (3) Fungal (1) HBV (1) HIV (1) HPV (1) HSV (1) Influenza Virus (2) Integrin (3) Interleukin Related (1) Isotope-Labeled Compounds (1) Itk (1) LAG-3 (1) LPL Receptor (4) Microtubule/Tubulin (1) NF-κB (1) Nucleoside Antimetabolite/Analog (1) PDI (1) Phosphatase (4) Potassium Channel (3) Proton Pump (1) ROR (3) RSV (1) SHP2 (1) Src (1) Tim3 (1)
By Research Areas:	Cancer (40) Infection (7) Inflammation/Immunology (43) Metabolic Disease (2) Neurological Disease (2)

By Targets:

Antibiotic (3)

Apoptosis (8)

Arenavirus (4)

Autophagy (4)

Bacterial (5)

CD28 (1)

CD3 (1)

CTLA-4 (5)

CXCR (1)

Deubiquitinase (1)

DOCK (1)

Drug Metabolite (3)

EBV (1)

EGFR (1)

Endogenous Metabolite (4)

Epigenetic Reader Domain (1)

Ferroptosis (1)

FKBP (3)

Fungal (1)

HBV (1)

HIV (1)

HPV (1)

HSV (1)

Influenza Virus (2)

Integrin (3)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

Itk (1)

LAG-3 (1)

LPL Receptor (4)

Microtubule/Tubulin (1)

NF-κB (1)

Nucleoside Antimetabolite/Analog (1)

PDI (1)

Phosphatase (4)

Potassium Channel (3)

Proton Pump (1)

ROR (3)

RSV (1)

SHP2 (1)

Src (1)

Tim3 (1)

By Research Areas:

Cancer (40)

Infection (7)

Inflammation/Immunology (43)

Metabolic Disease (2)

Neurological Disease (2)

Inhibitors & Agonists

スクリーニングライブラリ

蛍光色素

生化学アッセイ試薬

ペプチド

阻害性抗体

Natural
Products

Isotope-Labeled Compounds

製品番号	製品名	Target	研究分野	構造式

HY-N10196

Cerebroside D	Endogenous Metabolite	Inflammation/Immunology
Cerebroside D, a glycoceramide compound, improves experimental colitis in mice with multiple targets against activated T lymphocytes .

HY-113963

Ac-IETD-CHO	Apoptosis	Cancer
Ac-?IETD-?CHO is a potent, reversible inhibitor of granzyme B and caspase-8. Ac-?IETD-?CHO inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac-?IETD-?CHO also inhibits cytotoxic T lymphocytes induced cell death .

HY-P99765

Odulimomab anti-LFA1	Integrin	Inflammation/Immunology
Odulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody. Odulimomab inhibits proliferation of T lymphocyte and shows protective effects against ischemia and reperfusion injury. Odulimomab can be used for the research of transplant rejection and immunological disease .

HY-14801

Sivifene A-007	Others	Inflammation/Immunology Cancer
Sivifene (A-007) is a triaryl hydrazone. Sivifene has anticancer activity and immunomodulatory effects. Sivifene regulates immune regulation by upregulating CD45 T lymphocyte surface receptors .

HY-18164

TASP0277308	LPL Receptor	Inflammation/Immunology
TASP0277308 is a highly selective S1P₁ antagonist. TASP0277308 possesses immunomodulatory activities, including lymphopenia, a block in T cell egress from the thymus, marginal zone B cell displacement, and the upregulation of CD69 expression on lymphocytes. TASP0277308 can be used for the research of collagen-induced arthritis in mice .

HY-142938

RORγt agonist 3	ROR	Inflammation/Immunology
RORγt agonist 3 is a potent agonist of RORγt. RORγt agonist 3 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 3 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136326A1, compound 23) .

HY-142937

RORγt agonist 2	ROR	Inflammation/Immunology
RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17) .

HY-139874

CXCR2 antagonist 3	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 3 (compound 11h) is a potent antagonist of CXC chemokine receptor 2 (CXCR2). CXCR2 antagonist 3 demonstrates double-digit nanomolar potencies against CXCR2 and significantly inhibited neutrophil infiltration into the air pouch. CXCR2 antagonist 3 reduces the infiltration of neutrophils and MDSCs and enhance the infiltration of CD3 ⁺ T lymphocytes into the Pan02 tumor tissues .

HY-147008

XP-524	Epigenetic Reader Domain	Cancer
XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .

HY-P3071

ShK toxin	Potassium Channel	Inflammation/Immunology
ShK toxin blocks voltage-dependent potassium channel (K_v1.3 channel). ShK toxin can be isolated from the whole body extract of the Caribbean sea anemone (Stichodactylu helianthus). ShK toxin competes with dendrotoxin I and α-dendrotoxin for binding to synaptosomal membranes of rat brain, facilitates acetylcholine release. ShK toxin suppresses K+ currents in cultured rat dorsal root ganglion neurons. ShK toxin also inhibits T lymphocyte proliferation .

HY-W013727

UK-78282 hydrochloride	Potassium Channel	Inflammation/Immunology
UK-78282, a novel piperidine, potent and selective Kv1.3 blocker with an IC₅₀ of 200 nM. UK-78,282 effectively suppresses human T-lymphocyte activation in vitro. UK-78,282 binds to residues at the inner surface of the channel overlapping the site of action of verapamil .

HY-P9948

Alemtuzumab Campath-IH	Apoptosis	Cancer
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .

HY-W107464

G6PDi-1	PDI	Metabolic Disease Inflammation/Immunology
G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC₅₀ of 0.07 μM for human G6PD. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells .

HY-162264

Tubulin polymerization/V-ATPase-IN-1	Microtubule/Tubulin Proton Pump Apoptosis	Inflammation/Immunology Cancer
Tubulin polymerization/V-ATPase-IN-1 (compound F10) is a Tubulin polymerization/V-ATPase inhibitor. Tubulin polymerization/V-ATPase-IN-1 shows robust antiproliferation activity against four human cancer cell lines, and exerts antiproliferative activity by inhibiting tubulin and V-ATPase. Tubulin polymerization/V-ATPase-IN-1 induces immunogenic cell death in addition to apoptosis, and inhibits tumor growth in an RM-1 homograft model with enhanced T lymphocyte infiltration .

HY-P3736

Myelopeptide-2 MP-2	Interleukin Related	Cancer
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research .

HY-153209

ISATM51

Others Others

ISATM51 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses .

ISATM51	Others	Others
ISATM51 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses .

HY-100731

Cyclosporin
Cyclosporin is a cyclic decapeptide that could be isolated form the soil fungi Tolypocladium inflatum. Cyclosporin is an immunosuppressant thought to bind to cyclophilin in T-lymphocytes .

HY-P9901

Ipilimumab 3 Publications Verification MDX-010; BMS-734016	CTLA-4	Cancer
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .

HY-P9918

Tremelimumab Ticilimumab; CP-675206	CTLA-4	Inflammation/Immunology Cancer
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .

HY-P990041

Firastotug	CTLA-4	Inflammation/Immunology Cancer
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .

HY-P3410

Trichomide A	SHP2 Phosphatase	Inflammation/Immunology
Trichomide A is a potent activator of SHP2. Trichomide A is a natural cyclodepsipeptide. Trichomide A displays immunosuppressive activity against activated T lymphocyte–mediated immune responses in Con A-activated T cells. Trichomide A have the potential for the research of immune-related skin diseases .

HY-P99484

Botensilimab AGEN 1181	CTLA-4	Cancer
Botensilimab (AGEN 1181), a human anti-*cytotoxic T-lymphocyte* antigen 4 (CTLA-4)** monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .

HY-P99760

Nurulimab BCD-145	CTLA-4	Cancer
Nurulimab (BCD-145) is an anti-*cytotoxic T lymphocyte* antigen-4 (anti-CTLA-4)** human monoclonal antibody. Nurulimab can be can be used in research of melanoma .

HY-160055

GMT 4 aptamer sodium	Others	Cancer
GMT 4 aptamer sodium is a nucleic acid aptamer targeting different glioblastoma cell lines and exhibits high affinity. GMT 4 aptamer sodium also shows high binding affinity to the T lymphocyte cell line CCRF-CEM .

HY-160057

GMT 8 aptamer sodium	Others	Cancer
GMT 8 aptamer sodium is a nucleic acid aptamer targeting different glioblastoma cell lines and exhibits high affinity. GMT 4 aptamer sodium also shows high binding affinity to the T lymphocyte cell line CCRF-CEM .

HY-B0078

Dacarbazine 5+ Cited Publications Imidazole Carboxamide	Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC₅₀ of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma .

HY-13756A

Tacrolimus monohydrate Maximum Cited Publications 68 Publications Verification FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate	Phosphatase FKBP Autophagy Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-107091

Aspartyl-alanyl-diketopiperazine DA-DKP	Others	Inflammation/Immunology
Aspartyl-alanyl-diketopiperazine (DA-DKP) is an immunomodulatory molecule generated by cleavage and cyclization from the N-terminus of human albumin and can modulate the inflammatory immune response through a molecular pathway implicated in T- lymphocyte anergy .

HY-13756

Tacrolimus Maximum Cited Publications 68 Publications Verification FK506; Fujimycin; FR900506	Phosphatase FKBP Bacterial Autophagy Antibiotic	Infection Inflammation/Immunology Cancer
Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-P1569

LCMV gp33-41 1 Publications Verification	Arenavirus	Inflammation/Immunology
LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .

HY-163028

ML-T7	Tim3	Cancer
ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .

HY-P1569A

LCMV gp33-41 TFA 1 Publications Verification	Arenavirus	Inflammation/Immunology
LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .

HY-125881

ASP1126	LPL Receptor	Inflammation/Immunology
ASP1126 is a selective and orally active sphingosine-1-phosphate (S1P) agonist, with EC₅₀ values of 7.12 nM, 517 nM for hS1P₁ and hS1P₃, respectively. ASP1126 decreases the number of peripheral lymphocytes, naive T cells, central memory T cells and effector memory T cells in the peripheral blood. ASP1126 has the potential to be applied in clinical transplantation with improved safety profile .

HY-P99961

Tifcemalimab JS004	CD28	Cancer
Tifcemalimab (JS004) is a humanized anti-*BTLA (B and T lymphocyte* attenuation factor)** monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer .

HY-160768

OTUB2-IN-1	Deubiquitinase	Inflammation/Immunology Cancer
OTUB2-IN-1, a specific inhibitor of OTUB2 (K_D: ~12 μM), reduces PD-L1 protein expression in tumor cells and inhibits tumor growth by promoting robust intra-tumor infiltration of cytotoxic T lymphocytes (CTL) .

HY-P1835

CEF8, Influenza Virus NP (383-391)	Influenza Virus	Inflammation/Immunology
CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B ^2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes*-mediated immunity .

HY-N6857

Armepavine	NF-κB	Inflammation/Immunology
Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades .

HY-P2521

NS2 (114-121), Influenza	Influenza Virus	Infection Inflammation/Immunology
NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructural protein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of CD8 ⁺ cytotoxic T lymphocyte (CTL) in antiviral immune responses .

HY-P10245

Fusion glycoprotein (92-106)	RSV	Inflammation/Immunology
Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratory syncytial virus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL) .

HY-19344

Lifitegrast 2 Publications Verification SAR 1118; SHP-606	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344A

Lifitegrast sodium 2 Publications Verification SAR 1118 sodium; SHP-606 sodium	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .

HY-P99387

TSR-033	LAG-3	Cancer
TSR-033 is a high affinity human IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), a co-receptor associated with impaired T cell function and often co-expressed with PD-1, that enhances T cell function and PD-1 blocking activity in vitro and in vivo. TSR-033 has anti-tumor activity .

HY-B0199

Mycophenolate Mofetil 5+ Cited Publications RS 61443; TM-MMF	Drug Metabolite Apoptosis Endogenous Metabolite Bacterial	Cancer
Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation .

HY-155516

KV1.3-IN-1	Potassium Channel	Inflammation/Immunology
KV1.3-IN-1 (Compound trans-18) is a KV1.3 channel inhibitor (IC₅₀: 230 nM and 26.12 nM in Ltk_? cells and PHA-activated T-lymphocytes respectively). KV1.3-IN-1 impairs intracellular Ca ²⁺ signaling. KV1.3-IN-1 inhibits T-cell activation, proliferation, and colony formation .

HY-P1862

HSV-gB2 (498-505)	HSV	Infection
HSV-gB2 (498-505) is an immunodominant epitope from herpes simplex virus (HSV) glycoprotein B residues 498-505, acts as H-2Kb-restricted and HSV-1/2-cross-reactive cytotoxic T-lymphocyte (CTL) recognition epitope .

HY-W009245

Bz-RS-iSer(3-Ph)-OMe	HIV	Infection
Bz-RS-iSer(3-Ph)-OMe (compound 2), a Taxol derivative, inhibits HSV replication cycle at low cytotoxicity, blocks mitotic divisions of Vero cells, influences M-MSV induced tumor size and affects immune response by inhibiting PHA-induced T lymphocyte proliferation .

HY-101939

RP-001	LPL Receptor	Neurological Disease
RP-001 is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC₅₀ of 9 pM. RP-00 induces internalization and polyubiquitination of S1P1. RP-001 has little activity on S1P2-S1P4 and only moderate affinity for S1P5 .

HY-101939A

RP-001 hydrochloride	LPL Receptor	Neurological Disease
RP-001 hydrochloride is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC₅₀ of 9 pM. RP-00 hydrochloride induces internalization and polyubiquitination of S1P1. RP-001 hydrochloride has little activity on S1P2-S1P4 and only moderate affinity for S1P5 .

HY-103317

NAADP

Others Inflammation/Immunology

NAADP, a nucleotide, is a Ca ²⁺-mobilizing second messenger. NAADP is essential for initiation of Ca ²⁺ signaling .

HY-104037

Cintirorgon 5+ Cited Publications LYC-55716	ROR	Cancer
Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival .

製品番号	製品名

HY-L031

Small Molecule Immuno-Oncology Compound Library

494 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 494 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

製品番号	製品名	Type

HY-153209G

ISATM51 (GMP)	蛍光色素
ISATM51 (GMP) is a GMP grade ISATM51. ISATM51 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses .

製品番号	製品名	Type

HY-153209G

ISATM51 (GMP)	生化学アッセイ試薬
ISATM51 (GMP) is a GMP grade ISATM51. ISATM51 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses .

製品番号	製品名	Target	研究分野

HY-106171

NBI-6024	ペプチド	Metabolic Disease
NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients .

HY-P5742

ELAAWCRWGFLLALLPPGIAG	ペプチド	Cancer
ELAAWCRWGFLLALLPPGIAG (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P5742A

ELAAWCRWGFLLALLPPGIAG TFA	ペプチド	Cancer
ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P3638

Binetrakin	ペプチド	Inflammation/Immunology
Binetrakin (Interleukin 4 (human)) is a T lymphocyte-derived pleiotrophic cytokine that affects a variety of cell types including B cells and T cells. Binetrakin induces differentiation of naive helper T cells (Th0 cells) to Th2 cells. Binetrakin can be used for the research of many biological .

HY-113963

Ac-IETD-CHO	Apoptosis	Cancer
Ac-?IETD-?CHO is a potent, reversible inhibitor of granzyme B and caspase-8. Ac-?IETD-?CHO inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac-?IETD-?CHO also inhibits cytotoxic T lymphocytes induced cell death .

HY-106374

Elpamotide	ペプチド	Cancer
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer .

HY-P3071

ShK toxin	Potassium Channel	Inflammation/Immunology
ShK toxin blocks voltage-dependent potassium channel (K_v1.3 channel). ShK toxin can be isolated from the whole body extract of the Caribbean sea anemone (Stichodactylu helianthus). ShK toxin competes with dendrotoxin I and α-dendrotoxin for binding to synaptosomal membranes of rat brain, facilitates acetylcholine release. ShK toxin suppresses K+ currents in cultured rat dorsal root ganglion neurons. ShK toxin also inhibits T lymphocyte proliferation .

HY-P3736

Myelopeptide-2 MP-2	Interleukin Related	Cancer
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research .

HY-P1870

OVA sequence (323-336)

ペプチド Inflammation/Immunology

OVA sequence (323-336) is a cognate helper T-lymphocyte peptide that is employed to enhance CTL epitope immunogenicity.
HY-P2495

OVA (241-270)

ペプチド Cancer

OVA (241-270), a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .
HY-P2495A

OVA (241-270) (TFA)

ペプチド Inflammation/Immunology

OVA (241-270) TFA, a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .

HY-P3410

Trichomide A	SHP2 Phosphatase	Inflammation/Immunology
Trichomide A is a potent activator of SHP2. Trichomide A is a natural cyclodepsipeptide. Trichomide A displays immunosuppressive activity against activated T lymphocyte–mediated immune responses in Con A-activated T cells. Trichomide A have the potential for the research of immune-related skin diseases .

HY-105039

Disomotide G209-2M; GP100:209-217(210M); MPS-22	ペプチド	Cancer
Disomotide (G209-2M) is a melanoma antigen that enhances the generation of cytotoxic T lymphocytes (CTL) recognizing native G209 as well as melanoma .

HY-P3333

KSPWFTTL	ペプチド	Inflammation/Immunology Cancer
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .

HY-P3333A

KSPWFTTL TFA	ペプチド	Inflammation/Immunology Cancer
KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .

HY-P1569

LCMV gp33-41 1 Publications Verification	Arenavirus	Inflammation/Immunology
LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .

HY-P10264

MAGE-3 peptide MAGE-3(168-176), human	ペプチド	Cancer
MAGE-3 peptide (MAGE-3 168-176, human) is a peptide encoded by human MAGE-3 gene, which is expressed in tumor cells, presented by HLA and recognized by cytolytic T lymphocytes (CTL) as tumor antigen .

HY-P1569A

LCMV gp33-41 TFA 1 Publications Verification	Arenavirus	Inflammation/Immunology
LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .

HY-P1835

CEF8, Influenza Virus NP (383-391)	Influenza Virus	Inflammation/Immunology
CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B ^2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes*-mediated immunity .

HY-P2521

NS2 (114-121), Influenza	Influenza Virus	Infection Inflammation/Immunology
NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructural protein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of CD8 ⁺ cytotoxic T lymphocyte (CTL) in antiviral immune responses .

HY-P10245

Fusion glycoprotein (92-106)	RSV	Inflammation/Immunology
Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratory syncytial virus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL) .

HY-P1862

HSV-gB2 (498-505)	HSV	Infection
HSV-gB2 (498-505) is an immunodominant epitope from herpes simplex virus (HSV) glycoprotein B residues 498-505, acts as H-2Kb-restricted and HSV-1/2-cross-reactive cytotoxic T-lymphocyte (CTL) recognition epitope .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte* (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P2524

MAGE-3 (271-279)	ペプチド	Cancer
MAGE-3 (271-279) is a 271-279 residue peptide derived from melanoma antigens encoded by MAGE-3. MAGE-3 is a cytolytic T lymphocyte (CTL)-defined MAGE-3 protein associated with the human leukocyte antigen (HLA)-A2 molecule. MAGE-3 is overexpressed in different human tumor types, including malignant melanoma, but not by normal tissues except for testis and placenta .

HY-P1920

CEF19, Epstein-Barr Virus latent NA-3A (458-466)	EBV	Inflammation/Immunology
CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .

HY-P3644

EEKLIVVAF

ペプチド Cancer

EEKLIVVAF is a pepitide, can be recognized on HLA-B44 by the anti-melanoma cytolytic T-cell (CTL) clone LB33- CTL-159/5 .

HY-P1571

Nucleoprotein (396-404) NP 396	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

HY-P1571A

Nucleoprotein (396-404) (TFA) NP 396 TFA	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) TFA is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) TFA is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

製品番号	製品名	Target	研究分野